Please assess the completion status of the following clinical trial:

Trial Title: A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 and \<70 years of age at initiation of treatment~* Body weight between 50 kg and 125 kg at baseline~* Chronic hepatitis C, genotype 1~* Chronic liver disease consistent with HCV infection~* Compensated liver disease (Child-Pugh Grade A)~Exclusion Criteria:~* Pregnant or lactating women, and male partners of pregnant women~* Chronic hepatitis C, genotype 2, 3, 4, 5 or 6~* Previous treatment with interferon or ribavirin~* Positive for hepatitis A, hepatitis B or HIV infection~* History or evidence of a medical condition associated with liver disease other than chronic hepatitis C~* Decompensated liver disease and/or liver disease Child-Pugh classification \>6~* Hepatocellular carcinoma~* History or evidence of esophageal bleeding~* Hemoglobinopathy, or any other cause for possible hemolysis~* Hb \<11 g/dL in women, \<12 g/L in males

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Peginterferon Alfa-2a Plus Ribavirin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).